Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

A comprehensive assessment of somatic mutation detection in cancer using whole-genome sequencing

  • Alioto, Tyler
  • Derdak, Sophia
  • Ribeca, Paolo
  • Castro Giner, Francesc
  • Beltran, Sergi
  • Raineri, Emanuele
  • Dabad, Marc
  • Heath, Simon
  • Gut, Marta
  • Gut, Ivo Glynne
Includes supplementary materials: online appendix; replication file, As whole-genome sequencing for cancer genome analysis becomes a clinical tool, a full understanding of the variables affecting sequencing analysis output is required. Here using tumour-normal sample pairs from two different types of cancer, chronic lymphocytic leukaemia and medulloblastoma, we conduct a benchmarking exercise within the context of the International Cancer Genome Consortium. We compare sequencing methods, analysis pipelines and validation methods. We show that using PCR-free methods and increasing sequencing depth to ∼100 × shows benefits, as long as the tumour:control coverage ratio remains balanced. We observe widely varying mutation call rates and low concordance among analysis pipelines, reflecting the artefact-prone nature of the raw data and lack of standards for dealing with the artefacts. However, we show that, using the benchmark mutation set we have created, many issues are in fact easy to remedy and have an immediate positive impact on mutation detection accuracy., We thank the DKFZ Genomics and Proteomics Core Facility and the OICR Genome Technologies Platform for provision of sequencing services. Financial support was provided by the consortium projects READNA under grant agreement FP7 Health-F4-2008-201418, ESGI under grant agreement 262055, GEUVADIS under grant agreement 261123 of the European Commission Framework Programme 7, ICGC-CLL through the Spanish Ministry of Science and Innovation (MICINN), the Instituto de Salud Carlos III (ISCIII) and the Generalitat de Catalunya. Additional financial support was provided by the PedBrain Tumor Project contributing to the ICGC, funded by German Cancer Aid (109252) and by the German Federal Ministry of Education and Research (BMBF, grants #01KU1201A, MedSys #0315416C and NGFNplus #01GS0883), the BMBF-funded ICGC projects on early-onset prostate cancer and malignant lymphoma (#01KU1001A, #01KU1002B) and via the BMBF-funded de.NBI HD-HuB network (#031A537A, #031A537C); the Ontario Institute for Cancer Research to PCB and JDM through funding provided by the Government of Ontario, Ministry of Research and Innovation; Genome Canada; the Canada Foundation for Innovation and Prostate Cancer Canada with funding from the Movember Foundation (PCB). P.C.B. was also supported by a Terry Fox Research Institute New Investigator Award, a CIHR New Investigator Award and a Genome Canada Large-Scale Applied Project Contract. The Synergie Lyon Cancer platform has received support from the French National Institute of Cancer (INCa) and from the ABS4NGS ANR project (ANR-11-BINF-0001-06). The ICGC RIKEN study was supported partially by RIKEN President’s Fund 2011, and the supercomputing resource for the RIKEN study was provided by the Human Genome Center, University of Tokyo. M.D.E., L.B., A.G.L. and C.L.A. were supported by Cancer Research UK, the University of Cambridge and Hutchison-Whampoa Limited. S.D. is supported by the Torres Quevedo subprogramme (MICINN) under grant agreement PTQ-12-05391. E.H. is supported by the Research Council of Norway under grant agreements 221580 and 218241 and by the Norwegian Cancer Society under grant agreement 71220—PR-2006-0433. We specially thank Jennifer Jennings for administrating the activity of the ICGC Verification Working Group and Anna Borrell for administrative support.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Outstanding hydrogen permeation through CO2-stable dual phase ceramic membranes

  • Escolástico Rozalén, Sonia|||0000-0002-7097-2425
  • Serra Alfaro, José Manuel|||0000-0002-1515-1106
  • Solis Díaz, Cecilia
  • Kjolseth, C.
[EN] Mixed electronic-and protonic-conducting composites made up of physical mixtures of La5.5WO11.25-delta-La0.87Sr0.13CrO3-delta (LWO-LSC) have been evaluated as H-2 separation membranes for operation at temperatures greater than 550 degrees C. The mixture of these two ion-conducting phases led to non-linear synergetic effects; i.e. unexpected enhancement of the total conductivity and well-balanced ambipolar conductivity, resulting in appealing H-2 permeation fluxes through robust ceramic membranes. The preparation, primary characterization, H-2 permeation and stability studies of various composites is presented. Mixing LWO and LSC phases makes it possible (1) to improve the LSC sintering behavior and to achieve very high membrane densities and (2) to obtain compounds with high total conductivity, higher than that shown for LWO and LSC, separately. The highest permeation rate is achieved for the 50 vol%-LWO-LSC membrane, though other composite compositions showed higher total conductivity. Moreover, the influence on the H-2 permeation of the composite composition, the humidification of gas streams, temperature and the use of various catalytic coatings on the membrane surface is evaluated. The nature of the transport mechanism is investigated by the permeation studies using deuterium tracers. The H-2 permeation rates reported in this investigation for a 370 mu m thick 50 vol%-LWO-LSC membrane, e.g. 0.15 mL min(-1) cm(-2) at 700 degrees C, are the highest reported values, up to date, for any bulk mixed protonic-electronic membranes. The H-2 permeation magnitude achieved at moderate temperatures along with the proven stability in CO2-rich atmospheres are firm steps towards the future application of this type of membrane for industrial processes., Financial support by the Spanish government (ENE2011-24761, CSD-2009-0050, and SEV-2012-0267) and the Helmholtz Association of German Research Centers through the portfolio topic MEM-BRAIN is kindly acknowledged. Protia acknowledges financial support from the Research Council of Norway (RCN) under the Gassmaks program ICOR (201418). The authors are indebted to M. Fabuel for sample preparation. The support of the Servicio de Microscopia Electronica of the Universidad Politecnica de Valencia is also acknowledged.
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

A comprehensive assessment of somatic mutation detection in cancer using whole-genome sequencing.

  • Alioto, Tyler S.
  • Buchhalter, Ivo
  • Derdak, Sophia
  • Hutter, Barbara
  • Eldridge, Matthew D.
  • Hovig, Eivind
  • Heisler, Lawrence E.
  • Beck, Timothy A.
  • Simpson, Jared T.
  • Tonon, Laurie
  • Sertier, Anne-Sophie
  • Patch, Ann-Marie
  • Jäger, Natalie
  • Ginsbach, Philip
  • Drews, Ruben
  • Paramasivam, Nagarajan
  • Kabbe, Rolf
  • Chotewutmontri, Sasithorn
  • Diessl, Nicolle
  • Previti, Christopher
  • Schmidt, Sabine
  • Brors, Benedikt
  • Feuerbach, Lars
  • Heinold, Michael
  • Gröbner, Susanne
  • Korshunov, Andrey
  • Tarpey, Patrick
  • Butler, Adam P.
  • Hinton, Jonathan
  • Jones, David T.W.
  • Menzies, Andrew
  • Raine, Keiran
  • Shepherd, Rebecca
  • Stebbings, Lucy
  • Teague, John W.
  • Ribeca, Paolo
  • Castro Giner, Francesc
  • Beltran i Agulló, Sergi
  • Raineri, Emanuele
  • Dabad, Marc
  • Heath, Simon C.
  • Gut, Marta
  • Denroche, Robert E.
  • Harding, Nicholas J.
  • Yamaguchi, Takafumi N.
  • Nakagawa, Hidewaki
  • Quesada, Victor
  • Valdés Mas, Rafael
  • Nakken, Sigve
  • Vodák, Daniel
  • Bower, Lawrence
  • Lynch, Andrew G.
  • Anderson, Charlotte L.
  • Waddell, Nicola
  • Pearson, John V.
  • Grimmond, Sean M.
  • Peto, Myron
  • Spellman, Paul
  • He, Minghui
  • Kandoth, Cyriac
  • Lee, Semin
  • Zhang, John
  • Létourneau, Louis
  • Ma, Singer
  • Seth, Sahil
  • Torrents Arenales, David
  • Xi, Liu
  • Wheeler, David A.
  • López-Otin, Carlos
  • Campo Güerri, Elias
  • Campbell, Peter J.
  • Boutros, Paul C.
  • Puente, Xose S.
  • Gerhard, Daniela S.
  • Pfister, Stefan M.
  • McPherson, John D.
  • Hudson, Thomas J.
  • Schlesner, Matthias
  • Lichter, Peter
  • Eils, Roland
  • Jones, David T.W.
  • Gut, Ivo G.
As whole-genome sequencing for cancer genome analysis becomes a clinical tool, a full understanding of the variables affecting sequencing analysis output is required. Here using tumour-normal sample pairs from two different types of cancer, chronic lymphocytic leukaemia and medulloblastoma, we conduct a benchmarking exercise within the context of the International Cancer Genome Consortium. We compare sequencing methods, analysis pipelines and validation methods. We show that using PCR-free methods and increasing sequencing depth to ∼ 100 × shows benefits, as long as the tumour:control coverage ratio remains balanced. We observe widely varying mutation call rates and low concordance among analysis pipelines, reflecting the artefact-prone nature of the raw data and lack of standards for dealing with the artefacts. However, we show that, using the benchmark mutation set we have created, many issues are in fact easy to remedy and have an immediate positive impact on mutation detection accuracy.
UPCommons. Portal del coneixement obert de la UPC
Publicación Artículo científico (JournalArticle)

A comprehensive assessment of somatic mutation detection in cancer using whole-genome sequencing

  • Alioto, Tyler S.
  • Buchhalter, Ivo
  • Derdak, Sophie
  • Torrents Rodas, David
As whole-genome sequencing for cancer genome analysis becomes a clinical tool, a full understanding of the variables affecting sequencing analysis output is required. Here using tumour-normal sample pairs from two different types of cancer, chronic lymphocytic leukaemia and medulloblastoma, we conduct a benchmarking exercise within the context of the International Cancer Genome Consortium. We compare sequencing methods, analysis pipelines and validation methods. We show that using PCR-free methods and increasing sequencing depth to ~100 × shows benefits, as long as the tumour:control coverage ratio remains balanced. We observe widely varying mutation call rates and low concordance among analysis pipelines, reflecting the artefact-prone nature of the raw data and lack of standards for dealing with the artefacts. However, we show that, using the benchmark mutation set we have created, many issues are in fact easy to remedy and have an immediate positive impact on mutation detection accuracy., Peer Reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

A comprehensive assessment of somatic mutation detection in cancer using whole-genome sequencing.

  • Alioto, Tyler S.
  • Buchhalter, Ivo
  • Derdak, Sophia
  • Hutter, Barbara
  • Eldridge, Matthew D.
  • Hovig, Eivind
  • Heisler, Lawrence E.
  • Beck, Timothy A.
  • Simpson, Jared T.
  • Tonon, Laurie
  • Sertier, Anne-Sophie
  • Patch, Ann-Marie
  • Jäger, Natalie
  • Ginsbach, Philip
  • Drews, Ruben
  • Paramasivam, Nagarajan
  • Kabbe, Rolf
  • Chotewutmontri, Sasithorn
  • Diessl, Nicolle
  • Previti, Christopher
  • Schmidt, Sabine
  • Brors, Benedikt
  • Feuerbach, Lars
  • Heinold, Michael
  • Gröbner, Susanne
  • Korshunov, Andrey
  • Tarpey, Patrick
  • Butler, Adam P.
  • Hinton, Jonathan
  • Jones, David T.W.
  • Menzies, Andrew
  • Raine, Keiran
  • Shepherd, Rebecca
  • Stebbings, Lucy
  • Teague, John W.
  • Ribeca, Paolo
  • Castro Giner, Francesc
  • Beltran i Agulló, Sergi
  • Raineri, Emanuele
  • Dabad, Marc
  • Heath, Simon C.
  • Gut, Marta
  • Denroche, Robert E.
  • Harding, Nicholas J.
  • Yamaguchi, Takafumi N.
  • Nakagawa, Hidewaki
  • Quesada, Victor
  • Valdés Mas, Rafael
  • Nakken, Sigve
  • Vodák, Daniel
  • Bower, Lawrence
  • Lynch, Andrew G.
  • Anderson, Charlotte L.
  • Waddell, Nicola
  • Pearson, John V.
  • Grimmond, Sean M.
  • Peto, Myron
  • Spellman, Paul
  • He, Minghui
  • Kandoth, Cyriac
  • Lee, Semin
  • Zhang, John
  • Létourneau, Louis
  • Ma, Singer
  • Seth, Sahil
  • Torrents Arenales, David
  • Xi, Liu
  • Wheeler, David A.
  • López-Otin, Carlos
  • Campo Güerri, Elias
  • Campbell, Peter J.
  • Boutros, Paul C.
  • Puente, Xose S.
  • Gerhard, Daniela S.
  • Pfister, Stefan M.
  • McPherson, John D.
  • Hudson, Thomas J.
  • Schlesner, Matthias
  • Lichter, Peter
  • Eils, Roland
  • Jones, David T.W.
  • Gut, Ivo G.
As whole-genome sequencing for cancer genome analysis becomes a clinical tool, a full understanding of the variables affecting sequencing analysis output is required. Here using tumour-normal sample pairs from two different types of cancer, chronic lymphocytic leukaemia and medulloblastoma, we conduct a benchmarking exercise within the context of the International Cancer Genome Consortium. We compare sequencing methods, analysis pipelines and validation methods. We show that using PCR-free methods and increasing sequencing depth to ∼ 100 × shows benefits, as long as the tumour:control coverage ratio remains balanced. We observe widely varying mutation call rates and low concordance among analysis pipelines, reflecting the artefact-prone nature of the raw data and lack of standards for dealing with the artefacts. However, we show that, using the benchmark mutation set we have created, many issues are in fact easy to remedy and have an immediate positive impact on mutation detection accuracy.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

A comprehensive assessment of somatic mutation detection in cancer using whole-genome sequencing

  • Alioto, Tyler
  • Derdak, Sophia
  • Ribeca, Paolo
  • Castro Giner, Francesc
  • Beltran, Sergi
  • Raineri, Emanuele
  • Dabad, Marc
  • Heath, Simon
  • Gut, Marta
  • Gut, Ivo Glynne
Includes supplementary materials: online appendix; replication file, As whole-genome sequencing for cancer genome analysis becomes a clinical tool, a full understanding of the variables affecting sequencing analysis output is required. Here using tumour-normal sample pairs from two different types of cancer, chronic lymphocytic leukaemia and medulloblastoma, we conduct a benchmarking exercise within the context of the International Cancer Genome Consortium. We compare sequencing methods, analysis pipelines and validation methods. We show that using PCR-free methods and increasing sequencing depth to ∼100 × shows benefits, as long as the tumour:control coverage ratio remains balanced. We observe widely varying mutation call rates and low concordance among analysis pipelines, reflecting the artefact-prone nature of the raw data and lack of standards for dealing with the artefacts. However, we show that, using the benchmark mutation set we have created, many issues are in fact easy to remedy and have an immediate positive impact on mutation detection accuracy., We thank the DKFZ Genomics and Proteomics Core Facility and the OICR Genome Technologies Platform for provision of sequencing services. Financial support was provided by the consortium projects READNA under grant agreement FP7 Health-F4-2008-201418, ESGI under grant agreement 262055, GEUVADIS under grant agreement 261123 of the European Commission Framework Programme 7, ICGC-CLL through the Spanish Ministry of Science and Innovation (MICINN), the Instituto de Salud Carlos III (ISCIII) and the Generalitat de Catalunya. Additional financial support was provided by the PedBrain Tumor Project contributing to the ICGC, funded by German Cancer Aid (109252) and by the German Federal Ministry of Education and Research (BMBF, grants #01KU1201A, MedSys #0315416C and NGFNplus #01GS0883), the BMBF-funded ICGC projects on early-onset prostate cancer and malignant lymphoma (#01KU1001A, #01KU1002B) and via the BMBF-funded de.NBI HD-HuB network (#031A537A, #031A537C); the Ontario Institute for Cancer Research to PCB and JDM through funding provided by the Government of Ontario, Ministry of Research and Innovation; Genome Canada; the Canada Foundation for Innovation and Prostate Cancer Canada with funding from the Movember Foundation (PCB). P.C.B. was also supported by a Terry Fox Research Institute New Investigator Award, a CIHR New Investigator Award and a Genome Canada Large-Scale Applied Project Contract. The Synergie Lyon Cancer platform has received support from the French National Institute of Cancer (INCa) and from the ABS4NGS ANR project (ANR-11-BINF-0001-06). The ICGC RIKEN study was supported partially by RIKEN President’s Fund 2011, and the supercomputing resource for the RIKEN study was provided by the Human Genome Center, University of Tokyo. M.D.E., L.B., A.G.L. and C.L.A. were supported by Cancer Research UK, the University of Cambridge and Hutchison-Whampoa Limited. S.D. is supported by the Torres Quevedo subprogramme (MICINN) under grant agreement PTQ-12-05391. E.H. is supported by the Research Council of Norway under grant agreements 221580 and 218241 and by the Norwegian Cancer Society under grant agreement 71220—PR-2006-0433. We specially thank Jennifer Jennings for administrating the activity of the ICGC Verification Working Group and Anna Borrell for administrative support.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

A comprehensive assessment of somatic mutation detection in cancer using whole-genome sequencing

  • Alioto, Tyler S.
  • Buchhalter, Ivo
  • Derdak, Sophie
  • Torrents Rodas, David
As whole-genome sequencing for cancer genome analysis becomes a clinical tool, a full understanding of the variables affecting sequencing analysis output is required. Here using tumour-normal sample pairs from two different types of cancer, chronic lymphocytic leukaemia and medulloblastoma, we conduct a benchmarking exercise within the context of the International Cancer Genome Consortium. We compare sequencing methods, analysis pipelines and validation methods. We show that using PCR-free methods and increasing sequencing depth to ~100 × shows benefits, as long as the tumour:control coverage ratio remains balanced. We observe widely varying mutation call rates and low concordance among analysis pipelines, reflecting the artefact-prone nature of the raw data and lack of standards for dealing with the artefacts. However, we show that, using the benchmark mutation set we have created, many issues are in fact easy to remedy and have an immediate positive impact on mutation detection accuracy., Peer Reviewed, Postprint (published version)